These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Radioimmunotherapy of human colon cancer xenografts with 131I-labeled anti-CEA monoclonal antibody.
    Author: Liu Z, Jin C, Yu Z, Zhang J, Liu Y, Zhao H, Jia B, Wang F.
    Journal: Bioconjug Chem; 2010 Feb 17; 21(2):314-8. PubMed ID: 20078028.
    Abstract:
    Radioimmunotherapy (RIT) is a promising approach for the treatment of a wide variety of malignancies. The aim of this study was to investigate the therapeutic efficacy of (131)I-labeled anticarcinoembryonic antigen (CEA) monoclonal antibody CL58 in a human colon cancer mouse model. In vitro and in vivo characteristics of (125)I-CL58 were evaluated in LS180 human colon cancer cells and the nude mouse model. (131)I-CL58 was prepared and its in vivo therapeutic efficacy was tested. (125)I-CL58 showed high affinity to LS180 cells, as well as high tumor uptake and long tumor retention in LS180 tumor xenografts. (131)I-CL58 exhibited dose-dependent inhibition of LS180 tumor growth. With the excellent in vitro and in vivo characteristics, and the effective therapy for colon cancer in animal model, (131)I-CL58 is a promising agent for RIT of CEA-positive tumors including colon cancer.
    [Abstract] [Full Text] [Related] [New Search]